# Filing Detail

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-23-056423
Filing Date
2023-07-12
Accepted
2023-07-12 15:10:31
Documents
5
Period of Report
2023-07-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | REPORT OF FOREIGN PRIVATE ISSUER | ea181678-6k_biondvax.htm | 6-K | 17751
2 | NOTICE AND PROXY STATEMENT | ea181678ex99-1_biondvax.htm | EX-99.1 | 146454
3 | PROXY CARD | ea181678ex99-2_biondvax.htm | EX-99.2 | 1882
4 | GRAPHIC | ex99-2_001.jpg | GRAPHIC | 537774
5 | GRAPHIC | ex99-2_002.jpg | GRAPHIC | 448532
| Complete submission text file | 0001213900-23-056423.txt |  | 1523815

Mailing Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000
Business Address JERUSALEM BIOPARK, 2ND FLOOR HADASSAH EIN KEREM CAMPUS JERUSALEM L3 00000 972-8-9302529
BiondVax Pharmaceuticals Ltd. (Filer) CIK: 0001611747 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-37353 | Film No.: 231084077
SIC: 2836 Biological Products, (No Diagnostic Substances)